Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 267 entries
View as:

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01445769 Org: User:
Start: 09/30/11 End: 04/30/13 Due: 04/30/14

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Phase: N/A Priority: Normal
NCT ID: NCT05593432 Org: User:
Start: 11/23/22 End: 02/26/24 Due: 02/26/25

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Phase: N/A Priority: Normal
NCT ID: NCT04831944 Org: User:
Start: 03/29/21 End: 03/11/22 Due: 03/11/23

A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants

Phase: N/A Priority: Normal
NCT ID: NCT06934980 Org: User:
Start: 06/18/25 End: 11/21/25 Due: 11/21/26

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02917993 Org: User:
Start: 12/20/16 End: 12/31/25 Due: 12/31/26

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03920852 Org: User:
Start: 05/30/19 End: 12/26/19 Due: 12/26/20

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Phase: N/A Priority: Normal
NCT ID: NCT04921969 Org: User:
Start: 07/19/21 End: 04/08/24 Due: 04/08/25

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Phase: N/A Priority: Normal
NCT ID: NCT03679767 Org: User:
Start: 01/09/19 End: 06/28/22 Due: 06/28/23

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Phase: N/A Priority: Normal
NCT ID: NCT05253807 Org: User:
Start: 04/29/22 End: 08/16/23 Due: 08/16/24

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03589651 Org: User:
Start: 08/17/18 End: 11/21/22 Due: 11/21/23

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Phase: N/A Priority: Normal
NCT ID: NCT06380205 Org: User:
Start: 05/07/24 End: 06/07/24 Due: 06/07/25

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03257644 Org: User:
Start: 09/21/17 End: 10/07/20 Due: 10/07/21

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT03584516 Org: User:
Start: 01/17/19 End: 11/03/23 Due: 11/03/24

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Phase: N/A Priority: Normal
NCT ID: NCT05696392 Org: User:
Start: 03/16/23 End: 01/22/25 Due: 01/22/26

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01604889 Org: User:
Start: 03/31/12 End: 12/27/16 Due: 12/27/17

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Phase: N/A Priority: Normal
NCT ID: NCT02752074 Org: User:
Start: 06/21/16 End: 08/16/19 Due: 08/16/20

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01929941 Org: User:
Start: 09/30/13 End: 08/31/14 Due: 08/31/15

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05577182 Org: User:
Start: 01/05/23 End: 08/03/26 Due: 08/03/27

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03522142 Org: User:
Start: 08/27/18 End: 09/20/25 Due: 09/20/26

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03011892 Org: User:
Start: 01/09/17 End: 03/12/18 Due: 03/12/19

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Phase: N/A Priority: Normal
NCT ID: NCT05593445 Org: User:
Start: 11/18/22 End: 12/21/23 Due: 12/21/24

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02723994 Org: User:
Start: 09/30/16 End: 02/01/26 Due: 02/01/27

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02119650 Org: User:
Start: 02/11/14 End: 06/21/16 Due: 06/21/17

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02712905 Org: User:
Start: 05/05/16 End: 04/14/22 Due: 04/14/23

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02355431 Org: User:
Start: 12/31/14 End: 09/30/15 Due: 09/30/16